

NPDR

Ivan J. Suñer, MD, Associate Professor
Duke University Eye Center

Introduction

We recently had the opportunity to evaluate the P200MA in our teaching hospital. Since installation we have been impressed by the image quality and additional value it has brought. We present below a case study demonstrating the value of Dynamic Ultra-widefield Fluorescein Angiography offered by the P200MA in patients with Diabetic Retinopathy.

History

The patient was a 79-year-old female, with a history of moderate to severe NPDR in both eyes. She had previous focal macular laser treatment.

Examination

The ability to see more than 80% of the retina in each image capture is clearly demonstrated. There is early evidence that a subset of patients with diabetic macular edema may have a component of peripheral nonperfusion, resulting in upregulation of VEGF and increased vascular permeability. It has been suggested that these patients may also benefit from scatter laser treatment to these areas of nonperfusion. It is worth highlighting that the resolution of the macula is excellent, allowing a clear view of the previously treated Clinically Significant Macular Edema (CSME), microaneurysms and dot hemorrhages.

Conclusion

Ultra widefield fluorescein angiography aids in the simultaneous assessment of macular and peripheral retinal circulation in retinovascular condition, allowing us to more precisely classify subtypes of these conditions and guide our therapies.

optos[®]




SEE MORE.

Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina. The Company has gained regulatory clearance (CE and FDA 510(k)) to market its second device - P200MA. The P200MA is aimed at the ophthalmic medical specialist, as opposed to the primary care market. It is designed to produce an angiographic retinal image called **optomap**[®] *fa* that supports medical procedures by providing enhanced diagnostic, monitoring and treatment capabilities. With a view of over 80% of the retina in a simultaneous, single image, Optos' technology provides an unequalled combination of widefield retinal imaging, speed and convenience for both practitioner and patient.


optomap[®] *fa*



optomap[®] *fa* image. Previously treated CSME, microaneurysms, and peripheral hemorrhages can be clearly seen.



Magnifying the same **optomap**[®] *fa* image provides a detailed view of the previously treated CSME and micro-aneurysms.



optomap[®] *plus* color image of the retina showing micro-aneurysms and dot & blot hemorrhages throughout the retina.

WWW.OPTOS.COM